Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

227

Participants

Timeline

Start Date

October 15, 2019

Primary Completion Date

January 15, 2025

Study Completion Date

December 31, 2025

Conditions
Metastatic Solid Tumor
Interventions
DRUG

Sacituzumab Govitecan-hziy

Administered intravenously

Trial Locations (65)

1200

Cliniques Universitaires UCL Saint-Luc, Brussels

2109

Macquarie University, North Ryde

2145

Blacktown Hospital, Westmead

2298

Calvary Mater Newcastle Hospital, Waratah

2576

Southern Highlands Cancer Center, Bowral

3168

Monash Medical Centre, Monash Health, Clayton

3220

The Andrew Love Cancer Centre, Geelong Hospital, Geelong

4101

Mater Cancer Centre, Mater Misericordiae Limited, South Brisbane

4217

Pindara Private Hospital, Benowa

5112

Lyell McEwin Hospital, Elizabeth Vale

6000

Grand Hopital de Charleroi asbl (GHdC), Charleroi

8035

Hospital Universitari Vall d'Hebron, Barcelona

10065

Memorial Sloan Kettering Cancer Center, New York

Weill Cornell Medicine - Upper East Side, New York

10467

Montefiore Medical Center, The Bronx

12208

New York Oncology Hematology - Albany Medical Center, Albany

21000

Centre George Francois Leclerc, Dijon

22031

Virginia Cancer Specialists, PC, Fairfax

24060

Blue Ridge Cancer Care - Wytheville, Blacksburg

28041

Hospital Universitario 12 de Octubre, Madrid

31059

Institut Claudius Régaud - IUCT Oncopole, Toulouse

33000

Institut Bergonie, Bordeaux

33305

Chang Gung Medical Foundation, Linkou Chang Gung Memorial Hospital, Taoyuan

37203

Tennessee Oncology, PLLC, Nashville

38801

North Mississippi Medical Center - Hematology and Oncology - Tupelo, Tupelo

40536

University of Kentucky Medical Center, Lexington

44106

University Hospitals Cleveland Medical Center, Cleveland

46010

Hospital Clínico Universitario de Valencia, Valencia

46804

PathGroup Labs, LLC, Fort Wayne

46845

Parkview Research Center, Fort Wayne

48109

University of Michigan Rogel Cancer Center, Ann Arbor

48201

Karmanos Cancer Institute, Detroit

62702

SIU School of Medicine, Simmons Cancer Institute at SIU, Springfield

63110

Washington University School of Medicine - Siteman Cancer Center, St Louis

63141

David C. Pratt Center, St Louis

71105

Christus Highland Cancer Treatment Center, Shreveport

72762

Highlands Oncology Group, Springdale

75702

Texas Oncology - Tyler, Tyler

77030

The University of Texas MD Anderson Cancer Center, Houston

80045

University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora

85308

USOR - Arizona Oncology - Glendale - Saguaro Cancer Center, Glendale

85395

Arizona Oncology Associates PC-HAL, Goodyear

89052

Comprehensive Cancer of Nevada, Las Vegas

90095

UCLA Hematology/Oncology, Los Angeles

90602

TRIO-US Central Administration, Whittier

94805

Institut Gustave Roussy, Villejuif

97401

Willamette Valley Cancer Institute and Research Center - Eugene, Eugene

98201

Providence Regional Cancer Partnership, Everett

99508

Alaska Oncology & Hematology, LLC, Anchorage

06520

Smilow Cancer Hospital at Yale, New Haven

T6G 1Z2

Cross Cancer Institute, Edmonton

N6A 5W9

London Health Sciences Centre- Victoria Hospital, London

H3T 1E2

Jewish General Hospital, Montreal

K1H 8L6

The Ottawa Hospital, Ottawa

Unknown

Hong Kong Integrated Oncology Centre, Central

Hong Kong Sanatorium & Hospital, Happy Valley

Queen Mary Hospital, Hong Kong

Hong Kong United Oncology Center, Kowloon

Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin

Changhua Christian Hospital, Changhua

Taipei TzuChi Hospital, New Taipei City

Chi Mei Medical Center, Tainan City

National Cheng Kung University Hospital, Tainan City

08041

Hospital de la Santa Creu i Sant Pau, Barcelona

08908

Institut Català d'Oncologia, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY